BARCELONA, Spain I July 11, 2023 I La Merie Publishing released its newest product reviewing the pipeline of Prolia & Xgeva Biosimilars:
Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review
Reference Products: Prolia & Xgeva
Target: RANKL (receptor activator of nuclear factor kappa-B ligand)
Product Category: Antibody
This product provides basic information on approved drugs and drug candidates in research and development as biosimilar antibodies of Prolia & Xgeva (denosumab).
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
- Project History with link to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for TSLP inhibitors (prerequisite: access to internet).
This product is delivered on the very same day by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
Denosumab binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.
Denosumab has been developed by Amgen and is commercialized by Amgen, Daiichi Sankyo (Japan rights) and BeiGene (only for Xgeva) under different brand names, depending on indication and territory. BeiGene began marketing Xgeva in China in July 2020.
- Prolia (Pralia in Japan) is approved for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of fracture.
- Xgeva (Ranmark in Japan) is approved for prevention of skeletal-related events such as pathological fractures in adults with advanced malignancies involving bone. It is also indicated for the treatment of giant cell tumor in bone.
Amgen lists the patent expirations on denosumab between 2021 and 2025.
Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product.
The report “Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/denosumab-prolia-xgeva-biosimilars-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 485
BARCELONA, Spain I July 11, 2023 I La Merie Publishing released its newest product reviewing the pipeline of Prolia & Xgeva Biosimilars:
Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review
Reference Products: Prolia & Xgeva
Target: RANKL (receptor activator of nuclear factor kappa-B ligand)
Product Category: Antibody
This product provides basic information on approved drugs and drug candidates in research and development as biosimilar antibodies of Prolia & Xgeva (denosumab).
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
- Project History with link to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for TSLP inhibitors (prerequisite: access to internet).
This product is delivered on the very same day by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
Denosumab binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.
Denosumab has been developed by Amgen and is commercialized by Amgen, Daiichi Sankyo (Japan rights) and BeiGene (only for Xgeva) under different brand names, depending on indication and territory. BeiGene began marketing Xgeva in China in July 2020.
- Prolia (Pralia in Japan) is approved for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of fracture.
- Xgeva (Ranmark in Japan) is approved for prevention of skeletal-related events such as pathological fractures in adults with advanced malignancies involving bone. It is also indicated for the treatment of giant cell tumor in bone.
Amgen lists the patent expirations on denosumab between 2021 and 2025.
Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product.
The report “Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/denosumab-prolia-xgeva-biosimilars-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 485
